Despite progress in lymphoid malignancies, most are still incurable and lead to the death of the patient. The University of Iowa/Mayo Clinic Lymphoma SPORE (UI/MC SPORE) is a highly successful translational research program that takes advantage of the combined strengths of the translational lymphoma programs of the Holden Comprehensive Cancer Center at the University of Iowa and the Mayo Clinic Comprehensive Cancer Center - two NCI-designated comprehensive cancer centers. During the prior funding period, the UI/MC has been highly productive. Scientific accomplishments include translational studies exploring the potential of a novel therapeutic agent, immunostimulatory CpG ODN, as a potential treatment for B cell malignancies, development of novel approaches to imaging that could impact on our understanding of lymphoma biology, and investigation into biomarkers that could have a significant impact on management of lymphoma. Five early phase therapeutic clinical trials have been opened as part of the UI/MC SPORE, including four studies that have accrued subjects at both Iowa and Mayo. Since initiation of the UI/MC SPORE in 2002, 96 subjects have been enrolled on therapeutic trials and 17 on novel imaging trials. DNA and extensive clinical data have been collected on 1331 subjects at Iowa and Mayo as part of the UI/MC Lymphoma SPORE Molecular Epidemiologic Resource which will be increasingly valuable as a tool for identifying genetic factors that contribute to lymphomagenesis and response to therapy. This renewal application is designed to accelerate the progress of the UI/MC SPORE and consists of four research projects, four core resources, and the Career Development and Developmental Research Programs. Specific projects are as follows: 1) A novel approach to the immunotherapy of B cell malignancies 2) Signal transduction inhibitor therapy for lymphoma 3) Biology and Epidemiology of APRIL and BLyS in B-cell NHL 4) Regulatory T-cells in the tumor microenvironment of B-cell non-Hodgkin lymphoma Core resources include Administration, Biostatistics and Bioinformatics, Biospecimens, and Clinical Research that supports both clinical trials and the Molecular Epidemiology Resource of the UI/MC SPORE. All units within the UI/MC SPORE work to draw on the resources of both institutions to expedite the translation of discoveries into new and better approaches to the prevention and treatment of lymphoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097274-09
Application #
7878119
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Program Officer
Nothwehr, Steven F
Project Start
2002-09-11
Project End
2012-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
9
Fiscal Year
2010
Total Cost
$2,251,952
Indirect Cost
Name
University of Iowa
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Maurer, M J; Habermann, T M; Shi, Q et al. (2018) Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol 29:1822-1827
Shenoy, Niraj; Creagan, Edward; Witzig, Thomas et al. (2018) Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly. Cancer Cell 34:700-706
Ammann, Eric M; Shanafelt, Tait D; Wright, Kara B et al. (2018) Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length. Leuk Lymphoma 59:643-649
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Chapuy, Bjoern; Stewart, Chip; Dunford, Andrew J et al. (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679-690
Leal, Alexis D; Allmer, Cristine; Maurer, Matthew J et al. (2018) Variability of performance status assessment between patients with hematologic malignancies and their physicians. Leuk Lymphoma 59:695-701
Leelakanok, Nattawut; Geary, Sean M; Salem, Aliasger K (2018) Antitumor Efficacy and Toxicity of 5-Fluorouracil-Loaded Poly(Lactide Co-glycolide) Pellets. J Pharm Sci 107:690-697
Ghesquières, Hervé; Larrabee, Beth R; Casasnovas, Olivier et al. (2018) A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts. Br J Haematol 180:286-290
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Fama, Angelo; Xiang, Jinhua; Link, Brian K et al. (2018) Human Pegivirus infection and lymphoma risk and prognosis: a North American study. Br J Haematol 182:644-653

Showing the most recent 10 out of 387 publications